PE20251276A1 - Anticuerpo anti-fgf23 o fragmento de anticuerpo del mismo - Google Patents
Anticuerpo anti-fgf23 o fragmento de anticuerpo del mismoInfo
- Publication number
- PE20251276A1 PE20251276A1 PE2025000354A PE2025000354A PE20251276A1 PE 20251276 A1 PE20251276 A1 PE 20251276A1 PE 2025000354 A PE2025000354 A PE 2025000354A PE 2025000354 A PE2025000354 A PE 2025000354A PE 20251276 A1 PE20251276 A1 PE 20251276A1
- Authority
- PE
- Peru
- Prior art keywords
- antibody
- amino acid
- fgf23
- seq
- sequence represented
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022128011 | 2022-08-10 | ||
| JP2022164256 | 2022-10-12 | ||
| PCT/JP2023/029098 WO2024034638A1 (ja) | 2022-08-10 | 2023-08-09 | 抗ｆｇｆ２３抗体又は該抗体断片 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20251276A1 true PE20251276A1 (es) | 2025-05-14 |
Family
ID=89851658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2025000354A PE20251276A1 (es) | 2022-08-10 | 2023-08-09 | Anticuerpo anti-fgf23 o fragmento de anticuerpo del mismo |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12606615B2 (https=) |
| EP (1) | EP4570910A1 (https=) |
| JP (1) | JP7820529B2 (https=) |
| KR (1) | KR20250049545A (https=) |
| CN (1) | CN119677855A (https=) |
| AU (1) | AU2023323589A1 (https=) |
| CL (1) | CL2025000362A1 (https=) |
| CO (1) | CO2025001429A2 (https=) |
| IL (1) | IL318893A (https=) |
| MX (1) | MX2025001617A (https=) |
| PE (1) | PE20251276A1 (https=) |
| TW (1) | TW202413406A (https=) |
| WO (1) | WO2024034638A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250049545A (ko) * | 2022-08-10 | 2025-04-11 | 쿄와 기린 가부시키가이샤 | 항fgf23 항체 또는 해당 항체 단편 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US160735A (en) | 1875-03-09 | Improvement in sash-holders | ||
| JPS5623587A (en) | 1979-08-03 | 1981-03-05 | Mitsuwa Seiki Co Ltd | Vane type compressor |
| JPS58110600A (ja) | 1981-12-25 | 1983-07-01 | Kyowa Hakko Kogyo Co Ltd | ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド |
| WO1985003934A1 (fr) | 1984-03-06 | 1985-09-12 | Takeda Chemical Industries, Ltd. | Proteine modifiee chimiquement et son procede de preparation |
| JPS60221091A (ja) | 1983-12-21 | 1985-11-05 | Kyowa Hakko Kogyo Co Ltd | 新規プロモ−タ− |
| JP2564268B2 (ja) | 1985-08-28 | 1996-12-18 | 協和醗酵工業株式会社 | 融合抗原ポリペプチド |
| ZA872705B (en) | 1986-04-22 | 1987-10-05 | Immunex Corporation | Human g-csf protein expression |
| JP2958019B2 (ja) | 1988-05-06 | 1999-10-06 | 住友製薬株式会社 | ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法 |
| JP2928287B2 (ja) | 1988-09-29 | 1999-08-03 | 協和醗酵工業株式会社 | 新規ポリペプチド |
| JPH02257891A (ja) | 1989-03-31 | 1990-10-18 | Kyowa Hakko Kogyo Co Ltd | 組換え動物細胞による蛋白質の製造 |
| JPH0322979A (ja) | 1989-06-19 | 1991-01-31 | Kyowa Hakko Kogyo Co Ltd | 新規プラスミノーゲン活性化因子 |
| JP3131322B2 (ja) | 1991-12-17 | 2001-01-31 | 協和醗酵工業株式会社 | 新規α２→３シアリルトランスフェラーゼ |
| JP3756946B2 (ja) | 1993-03-29 | 2006-03-22 | 協和醗酵工業株式会社 | α１，３−フコシルトランスフェラーゼ |
| ES2233974T3 (es) | 1995-09-11 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana. |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| EP3960855A1 (en) | 2001-12-28 | 2022-03-02 | Chugai Seiyaku Kabushiki Kaisha | Method for stabilizing proteins |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| EP1810979B1 (en) | 2004-09-22 | 2012-06-20 | Kyowa Hakko Kirin Co., Ltd. | STABILIZED HUMAN IgG4 ANTIBODIES |
| JP5142707B2 (ja) * | 2005-02-08 | 2013-02-13 | 一般財団法人化学及血清療法研究所 | 抗体の改良方法 |
| US7883705B2 (en) | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
| KR101680906B1 (ko) * | 2007-09-26 | 2016-11-30 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| ES2697535T3 (es) | 2009-06-11 | 2019-01-24 | Inter Univ Research Institute Corporation Research Organization Of Information And Systems | Procedimiento para la producción de proteína |
| BR112021019337A2 (pt) | 2019-03-29 | 2021-12-07 | Atarga Llc | Anticorpo anti-fgf23 |
| JP7082305B1 (ja) | 2021-02-22 | 2022-06-08 | 株式会社ミクシィ | 情報処理装置、情報処理方法及びプログラム |
| JP7745359B2 (ja) | 2021-04-16 | 2025-09-29 | 株式会社Ｓｃｒｅｅｎホールディングス | 基板処理方法、基板処理装置および乾燥処理液 |
| KR20250049545A (ko) * | 2022-08-10 | 2025-04-11 | 쿄와 기린 가부시키가이샤 | 항fgf23 항체 또는 해당 항체 단편 |
-
2023
- 2023-08-09 KR KR1020257003983A patent/KR20250049545A/ko active Pending
- 2023-08-09 AU AU2023323589A patent/AU2023323589A1/en active Pending
- 2023-08-09 PE PE2025000354A patent/PE20251276A1/es unknown
- 2023-08-09 EP EP23852600.8A patent/EP4570910A1/en active Pending
- 2023-08-09 CN CN202380058877.3A patent/CN119677855A/zh active Pending
- 2023-08-09 JP JP2024540509A patent/JP7820529B2/ja active Active
- 2023-08-09 TW TW112129893A patent/TW202413406A/zh unknown
- 2023-08-09 WO PCT/JP2023/029098 patent/WO2024034638A1/ja not_active Ceased
- 2023-08-09 IL IL318893A patent/IL318893A/en unknown
-
2024
- 2024-11-29 US US18/964,217 patent/US12606615B2/en active Active
-
2025
- 2025-02-06 CL CL2025000362A patent/CL2025000362A1/es unknown
- 2025-02-07 MX MX2025001617A patent/MX2025001617A/es unknown
- 2025-02-10 CO CONC2025/0001429A patent/CO2025001429A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2025000362A1 (es) | 2025-10-10 |
| CN119677855A (zh) | 2025-03-21 |
| IL318893A (en) | 2025-04-01 |
| JP7820529B2 (ja) | 2026-02-25 |
| CO2025001429A2 (es) | 2025-05-19 |
| WO2024034638A1 (ja) | 2024-02-15 |
| AU2023323589A1 (en) | 2025-02-27 |
| JPWO2024034638A1 (https=) | 2024-02-15 |
| KR20250049545A (ko) | 2025-04-11 |
| MX2025001617A (es) | 2025-03-07 |
| EP4570910A1 (en) | 2025-06-18 |
| TW202413406A (zh) | 2024-04-01 |
| US20250163140A1 (en) | 2025-05-22 |
| US12606615B2 (en) | 2026-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| BR0310088A (pt) | Pré-direcionamento de droga por meio de anticorpos biespecìficos e constructos haptênicos compreendendo um veìculo peptìdico e o(s) agente(s) ativo(s) | |
| PE20240813A1 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodo para su uso | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| CO2023002206A2 (es) | Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas trem2 | |
| MX2021009622A (es) | Metodos para tratar la colestasis. | |
| PE20141159A1 (es) | Metodos para tratar o prevenir trastornos relacionados con el colesterol | |
| PE20251276A1 (es) | Anticuerpo anti-fgf23 o fragmento de anticuerpo del mismo | |
| PE20080430A1 (es) | Anticuerpo antagonista para el tratamiento del cancer | |
| ECSP088753A (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
| JOP20230283A1 (ar) | أنظمة مضادة لـ vegf ممتدة عالية الجرعة لعلاج الاضطرابات وعائية المنشأ بالعين | |
| PE20160994A1 (es) | Compuestos al receptor-3 del factor de crecimiento del fibroblasto (fgfr3) y metodos de tratamiento | |
| PE20220570A1 (es) | Anticuerpo anti-epha4 humano | |
| MX2023004299A (es) | Direccionamiento de células t cd4+ in vivo para terapeuticos de arnm. | |
| PE20231105A1 (es) | Moleculas de union a antigeno multi-especificas contra el vih y metodos de uso | |
| CL2022001984A1 (es) | Composiciones métodos para aumentar, mejorar transducción vectores de terapia génica y para eliminar, reducir inmunoglobulinas | |
| WO2020142740A8 (en) | Treatment of sjogren's disease with nuclease fusion proteins | |
| MX2022002418A (es) | Composiciones y metodos de tratamiento de enfermedades vasculares. | |
| CL2024004097A1 (es) | Anticuerpo que se une al n-terminal del factor-d maduro humano; productos relacionados | |
| UY39083A (es) | Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria | |
| CO2025002301A2 (es) | Anticuerpos anti-ccr8 y métodos de uso | |
| CO2023005942A2 (es) | Composiciones farmacéuticas de un inhibidor de cinasa | |
| AR121441A1 (es) | Anticuerpos anti-axl y composiciones | |
| WO2023141176A3 (en) | Neutralizing antibodies and antigen-binding fragments thereof against omicron and other coronavirus variants, and methods of making and using the same | |
| AR108790A1 (es) | Métodos y composiciones para el tratamiento de la enfermedad celíaca, de la sensibilidad al gluten no celíaca y de la enfermedad celíaca refractaria |